Clinical Trial Update: A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anakinra to prevent CAR-T cell–mediated neurotoxicity in Non-Hodgkin lymphoma; the study is completed and results were posted in May 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Marcela V. Maus, M.D.,Ph.D. | Conditions: Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-05-04